The American health care giant will pay $1 billion to the Irish drug maker Elan to gain access to Alzheimer’s disease treatments.
By DAVID JOLLY, NY Times: Business
Thu, 07/02/2009 - 6:11am
The American health care giant will pay $1 billion to the Irish drug maker Elan to gain access to Alzheimer’s disease treatments.